Brian Goodman, Ph.D.

Dr. Brian Goodman is a Partner at MPM BioImpact. He is responsible for leading investments and new company creation activities. Brian is a co-founder and a member of the Board of Directors of Aktis Oncology and ReNAgade Therapeutics and serves as a member of the Board of Directors of Antiva Biosciences and Orna Therapeutics.  He has also played key leadership roles at portfolio companies during the early stages of development, including leading Business Development at Orna and ReNAgade and serving as Chief Operations Officer and Chief Business Officer at Aktis Oncology.

Prior to joining MPM BioImpact, Brian co-founded Evelo Biosciences (NASDAQ: EVLO) and served as Head of Technology and Innovation.  Before taking the operational role at Evelo, Brian was a Senior Associate at Flagship Pioneering. Brian has worked across a diverse span of science, drug discovery, and development including the microbiome, extracellular vesicles, nonviral delivery, RNA medicines, and radiopharmaceuticals.  He is an inventor on multiple patent applications.

Brian holds a Ph.D. in Biological Chemistry and Molecular Pharmacology from Harvard Medical School, and B.S. and B.A. degrees in biochemistry and economics, respectively, from Brandeis University.